Effect of serum on fibroblasts and macrophages in patients with primary liver cancer before and after TACE and the effect of Jiedu recipe
- Conditions
- Primary liver cancer
- Registration Number
- ITMCTR2200005664
- Lead Sponsor
- Shanghai Changhai Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
(1) Patients with primary liver cancer diagnosed according to the diagnostic and therapeutic specifications for primary liver cancer (2019 Edition) are classified as stage B in Barcelona;
(2) Patients should not receive any Chinese herbal medicine and systemic treatment in the past two weeks;
(3) ECoG (Eastern Cooperative Oncology Group) score 0-1;
(4) Compensatory liver function, or child Pugh grade A or B;
(5) Patients need a life expectancy of at least 3 months;
(6) Voluntarily accept the treatment of this study protocol and sign the informed consent form.
(1) Taking drugs that may affect the evaluation observation indexes during the trial;
(2) The child Pugh score of liver function was grade C;
(3) WBC < 2.0 × 10 ^ 9 / L, platelet < 30 × 10^9/L
(4) Tumors accounted for more than 70% of the whole liver;
(5) Patients with serious primary diseases such as cardio cerebrovascular, liver, kidney and hematopoietic system and psychosis;
(6) Those who fail to take drugs according to the regulations after informed consent, cannot judge the curative effect, or incomplete data affect the judgment of curative effect.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method PFS;
- Secondary Outcome Measures
Name Time Method